Zimmer Biomet Holdings
✦ Quant Fair Value how this is computed
- Implied fair-value range of 50.25-278.29, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -38.5% below the average-multiple fair value of 164.27.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Zimmer Biomet Holdings (ZBH) | 19.13B | 25.53 | 1.50 | 0.95% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 18.7% below Morningstar's fair value estimate.
Analyst note
Zimmer Biomet reported second-quarter results that included a constant-currency topline of 5% and flat adjusted EPS growth, driven by trauma and extremities, as well as technology and data.
Why it matters: The firm had undertaken a number of key initiatives to position itself for accelerated growth. This included morphing the US sales force into groups that would be dedicated to specific specialty areas. Now we're seeing some green shoots in the businesses that were first to shift to this model, including upper extremities and technology, which grew in the upper single digits and the 20s, respectively. We were also pleased to see hips up 5% in constant currency, which suggests Zimmer Biomet is generally growing its hips at pace with the market.
The bottom line: Our minor adjustments didn't move the needle; thus, we're leaving our $130 fair value estimate unchanged. We saw little in the quarter to shift our thinking on Zimmer Biomet's wide economic moat. We estimate the firm can increase revenue by 4% in 2026 and that margins will remain generally flat year over year as the firm completes the process of reorganizing and training its commercial organization.
Long view: Several developments in the quarter particularly struck us. First, management's comments that capital spending by hospitals remains healthy came as good news to us, though we remain watchful that this might shift over the ensuing quarters. Second, Zimmer Biomet is making good headway placing Rosa robots. This is reassuring, as the robot helps with product pull through, especially now that large joints and shoulders can be done on Rosa. Third, the enthusiastic reaction in Japan to the iodine-coated hip implant bodes well for the firm, where this product received the Food and Drug Administration's breakthrough device designation. This hip could be approved in the US as early as 2027.
Considering infection of the implant continues to be one of the most common complications of large joint replacement and treating it can be very involved and costly, any improvements in the implant that could prevent infection would be welcomed by practitioners. The two-stage protocol for revision surgery in an infected hip runs from $40,000 to $100,000 in the US. Thus, even a slight reduction in hip implant infections could add up to significant healthcare savings.
Fair value
We’re trimming our fair value estimate by $10 to $120 per share, reflecting more pessimistic expectations for 2027, including slightly higher spending on sales and marketing as the firm continues to reorganize its US sales force. We hold a tempered view top-line growth and operating leverage from 2028 to 2030. While the firm had increased its top-line growth to match our low- to mid-single-digit range over the last three years, we think the easy profitability gains have been realized, and future improvement will be incremental and more challenging, especially considering the pressure from rising input, energy, and fuel costs. Additionally, we expect Zimmer Biomet's relatively lower price premium on its new cementless knee (compared with rival Stryker) to also drag on the value of product pull-through.
Over the longer term, we anticipate the more widespread use of Persona Osseoti, ongoing placement of Rosa, Tmini, and Monogram robots (as well any additional digital technologies), and associated product pull-through will be the main growth drivers. This translates into average annual top-line growth of 3% through 2030, which incorporates the roughly 200 basis points of price headwinds that have characterized large joints of late.
Operating margin bottomed out at 19% in 2020 and had recovered 540 basis points by 2025. This was driven by the resumption of procedure volume and the shedding of the dental and spine businesses early in 2022. Though management has held out 30% operating margin as a long-term goal, we’ve taken a more cautious view and assume it will reach 28% by the end of our explicit forecast period.
Economic moat
Zimmer's wide Morningstar Economic Moat Rating stems from two major sources. First, there are substantial switching costs for orthopedic surgeons. The extensive instrumentation, or tool sets, used to prepare bones and install implants are specific to each company. The learning curve to become proficient in using one company's instrumentation is significant. Additionally, relative to other specialists, an orthopedic surgeon's skill and experience play an outsize role in the clinical outcome for the patient. These issues all leave surgeons reluctant to train and master multiple instrumentation systems, especially if procedure volume is too low to maintain a high surgical facility with more than one system. Surgeons' preferences for certain vendors can stretch back to their days in residency training. Research has found that surgeons tend to stick with their preferred vendor and sales representative for five to 15 years, using that vendor for approximately 95% of their orthopedic procedures during that time. Switching to another instrumentation system would require taking time out for training, developing a relationship with a new sales rep, and working less efficiently during the early period of mastering another vendor's tools, possibly raising risks for the patient and reducing the number of procedures (and income for the surgeon). This dynamic explains why market share among the four top orthopedic implant makers has remained remarkably steady.
Zimmer's moat also involves intangible assets, including intellectual property that protects the product portfolio, which is characterized by evolutionary changes to technology, because new generations of products rely on intellectual property established by earlier iterations of those devices. Following changes to patent law introduced in 2012, the US switched to a first-inventor-to-file system from a first-to-invent system. We think this change favors the moats of the larger orthopedic players like Zimmer. The new system encourages inventors to file an application as soon as possible. Inventors will also need to provide more detailed applications in order to head off competitors that may block improvement patents in future generations of products. The new law also mandates an opposition review after the patent has been granted. This will result in more challenges to patents. We think firms like Zimmer, which can support an extensive legal team, will be in a better position to take advantage of the new law by filing comprehensive patent applications on an accelerated timeline and mounting complex and time-consuming challenges to patents granted to competitors.
We think another intangible asset is the relationship between the sales rep and the surgeon. Orthopedic sales reps play a critical role for the surgeons. The sales rep is present for every procedure, teaches the surgeon how to use each tool in the kit, and prepares a selection of instrumentation in all the right sizes and sequence for the procedure according to individual surgeon preference. For many orthopedic surgeons, who may perform 20-40 hip replacements and 50-70 knee replacements in a year, the sales rep provides a valuable service. For the small group of high-volume surgeons, who may be performing multiple knee replacements in a day, there is less need for any training by the sales rep, and the surgeon may wish to hire a nurse who can handle the procedure preparation.
From an environmental, social, and governance perspective, we see little that would inflict damage on our wide moat rating for Zimmer Biomet. The two most prominent areas of potential concern focus on product governance and intellectual property. As with all medical device companies, there is a risk of infrequent product recalls. Recalls tend to be less frequent in orthopedics than in cardiac devices, and they usually do not involve death because the products are typically not life-saving. Moreover, the most common device recalls involve packaging and labeling—not the underlying product. In the event of a recall that is associated with design flaws or manufacturing issues, orthopedic firms typically rely on new engineering to address the underlying product issue, or they simply discontinue the product. For the large competitors, such as Zimmer Biomet, it is relatively easy to direct patients to other products in the portfolio. All of these defensive actions do not fundamentally alter the surgeons’ high switching costs that underpin the moat.
As for intellectual property, competitive conflicts over IP are common in the industry, but less material when it comes to the moat. This partially reflects the ability of competitors to engineer their way around intellectual property. It is also associated with the propensity among medical device makers to cross-license or settle these IP disagreements, so that all competitors can return to selling their generally differentiated products. We largely view the defense of patents as a mechanism to keep smaller, emerging upstarts from entering the market.
Bull case
Zimmer Biomet has made impressive progress in placing its Rosa robots in hospitals and ambulatory surgical centers, paving the way for higher-margin implant pull-through.
Orthopedic surgeons often resist efforts by hospitals or health systems to limit their autonomy (and brand choice), which is one major factor that has contributed to the consistent failure of most programs put forth by providers.
Zimmer has amassed an impressive portfolio of patents, owning or controlling approximately 4,500 issued patents and applications worldwide.
Bear case
The scarcity of high-quality comparative effectiveness research data makes it more difficult for orthopedic companies to secure premium pricing at the same time payers and hospitals are raising the bar for cost-effectiveness.
While Zimmer's Persona knee system offers opportunities for further customization, it also means more complications for inventory management (without clear clinical benefit).
Zimmer Biomet must improve procedure volume and top-line growth so that operating leverage moves in the positive direction.
By Debbie S. Wang
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zimmer Biomet Holdings discussion 0 comments